Skip to main content

Breadcrumb

  1. Home

Cardiovascular

Valid for Measure Submission

Evaluation of Left ventricular systolic function (LVS)

  • Percentage of heart failure patients with documentation in the hospital record that left ventricular systolic (LVS) function was evaluated before arrival, during hospitalization, or is planned for after discharge.

    CBE ID
    0135

Fall 2022 Post-Comment Meeting

Following the conclusion of the Fall 2022 public comment period, the project committee reviews submitted comments. After its review, the committee may choose to revise its recommendations within in response to a specific comment or series of comments. In addition the project committee will re-vote on measures in which consensus was not reached during the Fall 2022 measure evaluaiton meeting. Any revisions will be reflected in the final report.

Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival

  • This measure calculates the percentage of Emergency Department (ED) acute myocardial infarction (AMI) patients with ST-segment elevation on the electrocardiogram (ECG) closest to arrival time receiving fibrinolytic therapy during the ED stay and having a time from ED arrival to fibrinolysis of 30 minutes or less. The measure is calculated using chart-abstracted data, on a rolling, quarterly basis and is publicly reported, in aggregate, for one calendar year.

    CBE ID
    0288

Fibrinolytic Therapy received within 30 minutes of hospital arrival

  • Percentage of acute myocardial infarction (AMI) patients with ST-segment elevation or LBBB on the ECG closest to arrival time receiving fibrinolytic therapy during the hospital stay and having a time from hospital arrival to fibrinolysis of 30 minutes or less.

    CBE ID
    0164

Fixed-dose Combination of Hydralazine and Isosorbide Dinitrate Therapy for Self-identified Black or African American Patients with Heart Failure and LVEF <40% on ACEI or ARB and Beta-blocker Therapy

  • Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) and a current or prior ejection fraction (EF) <40% who are self-identified Black or African Americans and receiving ACEI or ARB and Beta-blocker therapy who were prescribed a fixed-dose combination of hydralazine and isosorbide dinitrate seen for an office visit in the measurement period in the outpatient setting or at each hospital discharge

    CBE ID
    2764e

Heart Failure (HF) : Patient Education

  • Percentage of patients who were provided with patient education on disease management and health behavior changes during one or more visit(s).

    CBE ID
    0082